Please upgrade your browser.
We recommend that [maximum allowable contrast dose] should be determined before the procedure and implemented whenever feasible, they write.
Medistem Panama, licensee of Medistem Inc., announced today issuance of US patent # 7,749,495 covering a new method for treating cancer that does not require use of chemotherapy or radiation. The procedure, which involves taking out patient cells, manipulating them, and re-introducing them into the body, has demonstrated positive results in patients with metastatic renal cell carcinoma, neuroblastoma, adenocarcinoma, breast cancer, sarcoma, and rectal cancer.
They claim exposure to unsafe levels of heavy metals and toxic materials
Rosetta Genomics, Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that a peer-reviewed article entitled "Accurate Molecular Classification of Renal Tumors Using MicroRNA Expression" has been published in the online version of The Journal of Molecular Diagnostics.
Epithelioid angiomyolipoma of kidney with atypical nuclear features and intranuclear inclusions on cytology
Described herein are the cytological findings of epithelioid angiomyolipoma (EAML) of the kidney with atypical nuclear features mistaken for renal cell carcinoma (RCC) in a 61-year-old male patient.
This article advances the case that targeting macrophage activation and phenotype is leading to new therapies in the treatment of many acute and chronic kidney diseases.
Pazopanib has been granted a conditional licence in the UK for first-line treatment of patients with advanced renal cell carcinoma.
If approved by the U.S. Food and Drug Administration (FDA), this will be one of the first diagnostic scans which can differentiate not only identify a tumors origin and location, but also provide data on the type (histology) of that tumor. Armed with this information, physicians and patients will be able to make more informed treatment choices.
Efficient tumor vaccination frequently requires adjuvant. Concomitant induction of an autoimmune response is discussed as a means to strengthen a weak tumor Agspecific response.
Duplicated 1q might be a secondary mutations associated with disease progression. Trisomy of 1q has also been linked to metastatic potential of colon and renal cell carcinomas.
|NeonCRM by Neon One|